1 to 10 of 25 literature results

• ETS rearrangements and prostate cancer initiation.

  The first recurrent translocation event in prostate cancer has been recently described; it results in the translocation of an ETS (E26 transformation …

  Authors: Brett S Carver, Jennifer Tran, Zhenbang Chen, Arkaitz Carracedo-Perez, Andrea Alimonti, Caterina Nardella, Anuradha Gopalan, Peter T Scardino, Carlos Cordon-Cardo, William Gerald,…

  Source: Nature. 2009 Feb 12

  View Full Text

• Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

  Chromosomal translocations involving the ERG locus are frequent events in human prostate cancer pathogenesis; however, the biological role of aberrant…

  Authors: Brett S Carver, Jennifer Tran, Anuradha Gopalan, Zhenbang Chen, Safa Shaikh, Arkaitz Carracedo, Andrea Alimonti, Caterina Nardella, Shohreh Varmeh, Peter T Scardino,…

  Source: Nature genetics. 2009 May

  View Full Text

• Identification of a tumour suppressor network opposing nuclear Akt function.

  The proto-oncogene AKT (also known as PKB) is activated in many human cancers, mostly owing to loss of the PTEN tumour suppressor. In such tumours, AK…

  Authors: Lloyd C Trotman, Andrea Alimonti, Pier Paolo Scaglioni, Jason A Koutcher, Carlos Cordon-Cardo, Pier Paolo Pandolfi

  Source: Nature. 2006 May 25

  View Free Full Text

• PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.

  Loss of the promyelocytic leukaemia (PML) tumour suppressor has been observed in several human cancers. The tumour-suppressive function of PML has bee…

  Authors: Rosa Bernardi, Ilhem Guernah, David Jin, Silvia Grisendi, Andrea Alimonti, Julie Teruya-Feldstein, Carlos Cordon-Cardo, M Celeste Simon, Shahin Rafii, Pier Paolo Pandolfi

  Source: Nature. 2006 Aug 17

  View Full Text

• Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events.

  The mammalian target of rapamycin (mTOR) represents a critical signaling crossroad where pathways commonly disrupted in cancer converge. We report her…

  Authors: Caterina Nardella, Zhenbang Chen, Leonardo Salmena, Arkaitz Carracedo, Andrea Alimonti, Ainara Egia, Brett Carver, William Gerald, Carlos Cordon-Cardo, Pier Paolo Pandolfi

  Source: Genes & development. 2008 Aug 15

  View Free Full Text

• NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.

  The tumor suppressor PTEN, a critical regulator for multiple cellular processes, is mutated or deleted frequently in various human cancers. Subtle red…

  Authors: Xinjiang Wang, Lloyd C Trotman, Theresa Koppie, Andrea Alimonti, Zhenbang Chen, Zhonghua Gao, Junru Wang, Hediye Erdjument-Bromage, Paul Tempst, Carlos Cordon-Cardo,…

  Source: Cell. 2007 Jan 12

  View Free Full Text

• Ubiquitination regulates PTEN nuclear import and tumor suppression.

  The PTEN tumor suppressor is frequently affected in cancer cells, and inherited PTEN mutation causes cancer-susceptibility conditions such as Cowden s…

  Authors: Lloyd C Trotman, Xinjiang Wang, Andrea Alimonti, Zhenbang Chen, Julie Teruya-Feldstein, Haijuan Yang, Nikola P Pavletich, Brett S Carver, Carlos Cordon-Cardo, Hediye Erdjument-Bromage,…

  Source: Cell. 2007 Jan 12

  View Free Full Text

• Intra-articular administration of hylan G-F 20 in patients with symptomatic hip osteoarthritis: tolerability and effectiveness in a large cohort study in clinical practice.

  OBJECTIVE: This prospective, observational, open study aimed to assess the efficacy and safety of hylan G-F 20 in a large cohort of patients with symp…

  Authors: Alberto Migliore, Sandro Tormenta, Umberto Massafra, Emanuele Bizzi, Francesca Iannessi, Andrea Alimonti, Mauro Granata

  Source: Current medical research and opinion. 2008 May

  View Full Text

• Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.

  OBJECTIVES:The aromatase inhibitors Anastrozole, Letrozole (type 2 nonsteroidal aromatase inhibitors: n-SAI) and Exemestane (type 1 steroidal aromatas…

  Authors: Paolo Carlini, Andrea Michelotti, Gianluigi Ferretti, Sergio Ricci, Diana Giannarelli, Manuela Pellegrini, Nicola Cresti, Serena Di Cosimo, Emilio Bria, Paola Papaldo,…

  Source: Cancer investigation. 2007 Mar

  View Full Text

• New approaches to prevent intestinal toxicity of irinotecan-based regimens.

  BACKGROUND: Irinotecan is a selective inhibitor of topoisomerase I, an enzyme part of the replication and transcription system of DNA. Irinotecan is e…

  Authors: Andrea Alimonti, Alain Gelibter, Ida Pavese, Francesco Satta, Francesco Cognetti, Gianluigi Ferretti, Debora Rasio, Aldo Vecchione, Mario Di Palma

  Source: Cancer treatment reviews. 2004 Oct

  View Full Text